Palantir Technologies Inc
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
PLTR$168.82-0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net income | $217,717 | $106,071 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 6,622 | 8,438 |
| Stock-based compensation | 155,339 | 125,651 |
| Unrealized and realized (gain) loss from marketable securities, net | 10,688 | 12,354 |
| Noncash consideration | (17,313) | (11,907) |
| Other operating activities | 3,531 | 5,592 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (134,959) | (121,884) |
| Prepaid expenses and other assets | 40,730 | 22,924 |
| Accounts payable and accrued liabilities | 22,395 | 4,704 |
| Contract liabilities | 18,760 | (6,849) |
| Other liabilities | (13,247) | (15,515) |
| Net cash provided by operating activities | 310,263 | 129,579 |
| Investing activities | ||
| Purchases of property and equipment | (6,184) | (2,664) |
| Purchases of marketable securities | (1,704,720) | (1,260,327) |
| Proceeds from sales and redemption of marketable securities | 350,627 | 751,746 |
| Other investing activities | (30,000) | — |
| Net cash used in investing activities | (1,390,277) | (511,245) |
| Financing activities | ||
| Proceeds from the exercise of common stock options | 66,584 | 83,840 |
| Repurchases of common stock | (17,998) | (9,000) |
| Taxes paid related to net share settlement of equity awards | (77,573) | — |
| Other financing activities | 90 | 408 |
| Net cash provided by (used in) financing activities | (28,897) | 75,248 |
| Effect of foreign exchange on cash, cash equivalents, and restricted cash | 3,980 | (4,024) |
| Net decrease in cash, cash equivalents, and restricted cash | (1,104,931) | (310,442) |
| Cash, cash equivalents, and restricted cash - beginning of period | 2,119,936 | 850,107 |
| Cash, cash equivalents, and restricted cash - end of period | $1,015,005 | $539,665 |
Theaccompanying notes are an integral part of these condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.